July 1, 2026 AlzeCure Pharma enters an out-licensing and collaboration agreement with QuantumCell ApS for the NeuroRestore ACD856 project
June 9, 2026 AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project
June 5, 2026 AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document
April 24, 2026 AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million
